<code id='B651EDB1CC'></code><style id='B651EDB1CC'></style>
    • <acronym id='B651EDB1CC'></acronym>
      <center id='B651EDB1CC'><center id='B651EDB1CC'><tfoot id='B651EDB1CC'></tfoot></center><abbr id='B651EDB1CC'><dir id='B651EDB1CC'><tfoot id='B651EDB1CC'></tfoot><noframes id='B651EDB1CC'>

    • <optgroup id='B651EDB1CC'><strike id='B651EDB1CC'><sup id='B651EDB1CC'></sup></strike><code id='B651EDB1CC'></code></optgroup>
        1. <b id='B651EDB1CC'><label id='B651EDB1CC'><select id='B651EDB1CC'><dt id='B651EDB1CC'><span id='B651EDB1CC'></span></dt></select></label></b><u id='B651EDB1CC'></u>
          <i id='B651EDB1CC'><strike id='B651EDB1CC'><tt id='B651EDB1CC'><pre id='B651EDB1CC'></pre></tt></strike></i>

          explore

          explore

          author:fashion    Page View:73
          Johnson & Johnson logo. -- health coverage from STAT.
          Chris O'Meara/AP

          Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

          Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

          advertisement

          In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Generate Biomedicines machine learning biotech raises $273M
          Generate Biomedicines machine learning biotech raises $273M

          AdobeBiotechstartupGenerateBiomedicines,whichusesartificialintelligencetofindnewdrugs,raised$273mill

          read more
          Apple is now the first public company to be valued at $3 trillion
          Apple is now the first public company to be valued at $3 trillion

          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

          read more

          Former Pear Therapeutics executives start new VC firm

          SerialbiotechentrepreneurBobLangerwillserveasanadvisertoT.rxCapital.PatGreenhouse/GlobeStaffExecutiv